Who are the leading pharmaceutical companies besides Hengrui Pharma?

Generally speaking, the big pharmaceutical industry is divided into two major sectors and seven sub-sectors. Among them, the two major sectors are: medicine and medicine.

About seven sub-industries, it can be divided as follows:

Represented by medicine, it can be divided into: medical service, medical business and medical devices.

Represented by drugs, it can be divided into: raw materials, chemical pharmaceuticals, biopharmaceuticals and traditional Chinese medicines.

The following are the best-performing leading stocks in various sub-sectors of the pharmaceutical industry.

1. Chemical pharmaceutical leader: Hengrui Pharma (600276). I won't introduce it here.

2. Innovative medicine service leader: Wuxi PharmaTech (603259). Is the company ahead in the world? Integrated, end to end? New drug research and development service platform. From 20 16 to the third quarter of 20 19, the company's return on net assets was 29%, 2 1%, 23% and 9.89% respectively. Operating income increased by 25%, 27%, 24% and 34% respectively. Net profit increased by 179%, 25%, 84% and -8% respectively.

3. Medical equipment faucet: Mindray Medical (300760). The company is the largest medical device listed company in China, and the market share of several production lines is in the top 3 in China. From 20 16 to the third quarter of 20 19, the company's return on net assets was 28%, 47%, 42% and 22% respectively. Operating income increased by 12%, 23%, 23% and 20% respectively. Net profit increased by 75%, 6 1%, 43% and 26% respectively.

4. Leading medical service: Aier Ophthalmology (3000 15). The company is one of the largest ophthalmic medical institutions in China, and a leading chain enterprise of private ophthalmic hospitals. From 20 16 to the third quarter of 20 19, the company's return on net assets was 2 1%, 2 1%, 18% and 20% respectively. Operating income increased by 26%, 49%, 34% and 26% respectively. Net profit increased by 30%, 33%, 35% and 37% respectively.

5. Biopharmaceutical leader: Vingosine (00066 1). The company's leading products are growth hormone series products and freeze-dried live attenuated varicella vaccine, which has obvious market competitive advantages. From 20 16 to the third quarter of 20 19, the company's return on equity was 15%, 16%, 20% and 2 1% respectively. Operating income increased by 20%, 465,438+0%, 365,438+0% and 365,438+0% respectively. Net profit increased by 26%, 36%, 52% and 47% respectively.

6. Leading blood products: Hualan Bio (002007). The company is a leading enterprise in the domestic blood products and vaccine products industry. From 20 16 to the third quarter of 20 19, the company's return on equity was 19%, 18%, 22% and 16% respectively. Operating income increased by 365%, 438+0%, 22%, 35% and 29% respectively. Net profit increased by 32%, 5%, 38% and 26% respectively.

7. Leading pharmaceutical business: Yifeng Pharmacy (603939). The company is a pharmaceutical retail chain enterprise focusing on Central China, South China and East China. From 20 16 to the third quarter of 20 19, the company's return on net assets were 10%, 10%, 12% and 9% respectively. Operating income increased by 365%, 438+0%, 28%, 43% and 58% respectively. Net profit increased by 27%, 40%, 32% and 35% respectively.

8. Chinese medicine leader: Pien Tze Huang (603939). Pien Tze Huang, the company's core product, has been well received by Chinese medicine circles at home and abroad? National treasure and famous medicine? , selected? Chinese time-honored brand? . From 20 16 to the third quarter of 20 19, the company's return on equity was 16%, 2 1%, 25% and 19% respectively. Operating income increased by 22%, 60%, 28% and 265,438+0% respectively. The net profit increased by 14%, 50%, 4 1% and 20% respectively.